PMID- 37262315
OWN - NLM
STAT- MEDLINE
DCOM- 20230904
LR  - 20230904
IS  - 2042-7158 (Electronic)
IS  - 0022-3573 (Linking)
VI  - 75
IP  - 9
DP  - 2023 Sep 1
TI  - Sacubitril/valsartan cardioprotective effect against cisplatin-induced 
      cardiotoxicity via modulation of VEGF/eNOS and TLR4/TNFalpha/IL6 signalling pathways.
PG  - 1237-1248
LID - 10.1093/jpp/rgad049 [doi]
AB  - OBJECTIVES: Drug-induced cardiac injury is a potentially preventable cause of 
      heart failure. Cisplatin (CIS) is a widely used chemotherapeutic agent 
      complicated with cardiotoxicity that limits its clinical application so we aimed 
      to evaluate the suspected cardioprotective effect of sacubitril/valsartan 
      (Sac/Val) against CIS cardiotoxic injury. METHODS: Forty male rats of Wistar 
      albino species were divided into four groups. group I received the vehicle; group 
      II was given the vehicle plus CIS (10 mg/kg) single i.p. on fifth day; group III 
      was given Sac/Val (30 mg/kg/d) orally for 7 days plus CIS (10 mg/kg) single i.p. 
      on fif5th day; group IV was given the same as group III plus nitro-omega-L-arginine 
      (L-NNA) (25 mg/kg/d) orally for 7 days. KEY FINDINGS: CIS-induced cardiotoxicity 
      and L-NNA co-administered group showed significant increases in cardiac enzymes, 
      toxic histopathological features, elevated heart weights, angiotensin II (Ang 
      II), neprilysin, malondialdehyde (MDA), inflammatory mediators, blood pressure 
      (BP) and caspase 3 expressions, but there are significant decreases in the 
      antioxidant parameters, vascular endothelial growth factor (VEGF) and endothelial 
      nitric oxide synthase (eNOS). However, the co-administration of Sac/Val could 
      ameliorate these changes of CIS. CONCLUSION: Sac/Val has an important 
      cardioprotective effect against CIS cardiotoxicity with the involvement of eNOS.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the Royal 
      Pharmaceutical Society. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Mahmoud Refaie, Marwa Monier
AU  - Mahmoud Refaie MM
AUID- ORCID: 0000-0001-6211-9558
AD  - Department of Pharmacology, Faculty of Medicine, Minia University, El-Minia, 
      Egypt.
FAU - Ahmed Rifaai, Rehab
AU  - Ahmed Rifaai R
AUID- ORCID: 0000-0002-7481-2656
AD  - Department of Histology and Cell Biology, Faculty of Medicine, Minia University, 
      El-Minia, Egypt.
FAU - Bayoumi, Asmaa M A
AU  - Bayoumi AMA
AD  - Department of Biochemistry, Faculty of Pharmacy, Minia University, El-Minia, 
      Egypt.
FAU - Shehata, Sayed
AU  - Shehata S
AD  - Department of Cardiology, Faculty of Medicine, Minia University, El-Minia, Egypt.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 17ERJ0MKGI (sacubitril)
RN  - Q20Q21Q62J (Cisplatin)
RN  - 0 (Interleukin-6)
RN  - 0 (Toll-Like Receptor 4)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 80M03YXJ7I (Valsartan)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
SB  - IM
MH  - Male
MH  - Rats
MH  - Animals
MH  - *Cardiotoxicity/prevention & control
MH  - *Vascular Endothelial Growth Factor A/therapeutic use
MH  - Cisplatin/toxicity
MH  - Interleukin-6
MH  - Toll-Like Receptor 4
MH  - Tumor Necrosis Factor-alpha
MH  - Rats, Wistar
MH  - Valsartan/pharmacology/therapeutic use
MH  - Nitric Oxide Synthase/metabolism
OTO - NOTNLM
OT  - Toll-like receptor
OT  - cardiotoxicity
OT  - cisplatin
OT  - interleukin 6
EDAT- 2023/06/01 23:42
MHDA- 2023/09/04 06:42
CRDT- 2023/06/01 14:42
PHST- 2023/02/23 00:00 [received]
PHST- 2023/05/10 00:00 [accepted]
PHST- 2023/09/04 06:42 [medline]
PHST- 2023/06/01 23:42 [pubmed]
PHST- 2023/06/01 14:42 [entrez]
AID - 7188194 [pii]
AID - 10.1093/jpp/rgad049 [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 2023 Sep 1;75(9):1237-1248. doi: 10.1093/jpp/rgad049.